Merck is close to finalizing a $1.3 billion cash acquisition of EyeBio, a company specializing in eye drugs, according to a report by the Wall Street Journal.

Reported 4 months ago

Merck & Co is close to finalizing a $1.3 billion cash acquisition of Eyebiotech, an ophthalmology biotechnology firm, with potential for an additional $1.7 billion in milestone payments, as reported by The Wall Street Journal. Eyebiotech focuses on developing treatments for sight-threatening diseases, with its lead drug, Restoret, targeting retinal diseases causing vision impairment. Merck's interest in acquisitions is driven by revenue concerns following the eventual patent expiration of its top-selling cancer drug Keytruda, which generated over $25 billion in sales in 2023.

Merck is close to finalizing a $1.3 billion cash acquisition of EyeBio, a company specializing in eye drugs, according to a report by the Wall Street Journal.

You may also interested in these wikis